Porton Advanced Supports LianLi Zhongda’s LM101 Injection in Securing IND Clearance, Marking Another Milestone in End-to-End CDMO Track Record
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced Powers Qihan Biotech’s Second FDA IND Approval for Allogeneic Dual-Targeting CAR-T Product
China-US Dual Filing Success:Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy
Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
